Brief: Beijing Luzhu Biotechnology Says Recombinant RSV Vaccine Approved For Clinical Trials In China
12/10/2026 16:30
BRIEF-Beijing Luzhu Biotechnology Says Recombinant RSV Vaccine Approved For Clinical Trials In China Oct 12 (Reuters) - Beijing Luzhu Biotechnology Co Ltd 2480.HK:
RECOMBINANT RSV VACCINE APPROVED FOR CLINICAL TRIALS IN CHINA
Further company coverage: 2480.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beijing Luzhu Biotechnology
See all newsBrief: Beijing Luzhu Biotechnology Says Recombinant RSV Vaccine Approved For Clinical Trials In China
Brief: Beijing Luzhu Biotechnology Posts FY Loss Before Tax Rmb150.4 Million
Brief: Beijing Luzhu Biotechnology Enters Facility Agreements With Commercial Banks For RMB570.0 Mln
Brief: Beijing Luzhu Biotechnology Says It Repurchased Total 1.4 Mln H Shares
Brief: Beijing Luzhu Biotechnology Says Applied For Approval Of Listing Of 59.7 Million H Shares